XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Additional Paid-in Capital
Treasury Stock, At Cost
Notes Receivable From Stockholders
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Balance at beginning of period at Jun. 30, 2023 $ 32 $ 401,087 $ (5,763) $ (97) $ (2,122) $ (331,441) $ 61,696
Balance at beginning of period (in shares) at Jun. 30, 2023 31,482            
Balance at beginning of period (in shares) at Jun. 30, 2023     786        
Interest on stockholder notes       (1)     (1)
Repayment of stockholder notes       77     77
Issuance of common stock upon exercise of stock options $ 1 573         574
Issuance of common stock upon exercise of stock options (in shares) 185            
Repurchase of common stock     $ (8,529)       (8,529)
Repurchase of common stock, shares (1,355)   1,355        
Issuance of common stock in connection with employee stock purchase plan   417         417
Issuance of common stock in connection with employee stock purchase plan (in shares) 70            
Stock-based compensation   3,513         3,513
Foreign currency translation adjustments         (160)   (160)
Net Income (Loss)           6,274 6,274
Balance at end of period at Mar. 31, 2024 $ 33 405,590 $ (14,292) (21) (2,282) (325,167) 63,861
Balance at end of period (in shares) at Mar. 31, 2024 30,382            
Balance at end of period (in shares) at Mar. 31, 2024     2,141        
Balance at beginning of period at Dec. 31, 2023 $ 32 404,320 $ (8,778) (20) (2,101) (326,660) 66,793
Balance at beginning of period (in shares) at Dec. 31, 2023 31,202            
Balance at beginning of period (in shares) at Dec. 31, 2023     1,260        
Interest on stockholder notes       (1)     (1)
Issuance of common stock upon exercise of stock options $ 1 160         161
Issuance of common stock upon exercise of stock options (in shares) 61            
Repurchase of common stock     $ (5,514)       (5,514)
Repurchase of common stock, shares (881)   881        
Stock-based compensation   1,110         1,110
Foreign currency translation adjustments         (181)   (181)
Net Income (Loss)           1,493 1,493
Balance at end of period at Mar. 31, 2024 $ 33 405,590 $ (14,292) (21) (2,282) (325,167) 63,861
Balance at end of period (in shares) at Mar. 31, 2024 30,382            
Balance at end of period (in shares) at Mar. 31, 2024     2,141        
Balance at beginning of period at Jun. 30, 2024 $ 33 407,416 $ (23,031) (21) (2,240) (323,661) $ 58,496
Balance at beginning of period (in shares) at Jun. 30, 2024 29,160            
Balance at beginning of period (in shares) at Jun. 30, 2024     3,538       3,538
Issuance of common stock upon exercise of stock options   488         $ 488
Issuance of common stock upon exercise of stock options (in shares) 161            
Issuance of common stock upon vesting of restricted stock units, (in shares) 169            
Repurchase of common stock     $ (12,017)       (12,017)
Repurchase of common stock, shares (1,986)   1,986        
Issuance of common stock in connection with employee stock purchase plan   424         424
Issuance of common stock in connection with employee stock purchase plan (in shares) 94            
Stock-based compensation   1,953         1,953
Foreign currency translation adjustments         853   853
Net Income (Loss)           1,389 1,389
Balance at end of period at Mar. 31, 2025 $ 33 410,281 $ (35,048) (21) (1,387) (322,272) $ 51,586
Balance at end of period (in shares) at Mar. 31, 2025 27,598            
Balance at end of period (in shares) at Mar. 31, 2025     5,524       5,524
Balance at beginning of period at Dec. 31, 2024 $ 33 409,551 $ (30,025) (21) (1,942) (322,338) $ 55,258
Balance at beginning of period (in shares) at Dec. 31, 2024 28,481            
Balance at beginning of period (in shares) at Dec. 31, 2024     4,629        
Issuance of common stock upon exercise of stock options   31         31
Issuance of common stock upon exercise of stock options (in shares) 12            
Repurchase of common stock     $ (5,023)       (5,023)
Repurchase of common stock, shares (895)   895        
Stock-based compensation   699         699
Foreign currency translation adjustments         555   555
Net Income (Loss)           66 66
Balance at end of period at Mar. 31, 2025 $ 33 $ 410,281 $ (35,048) $ (21) $ (1,387) $ (322,272) $ 51,586
Balance at end of period (in shares) at Mar. 31, 2025 27,598            
Balance at end of period (in shares) at Mar. 31, 2025     5,524       5,524